Sammy Karam - 18 Feb 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Sammy Karam by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
18 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 19:16:58 UTC
Previous filing
28 Dec 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +59,708 $0.000000 59,708 18 Feb 2022 Common Shares 59,708 $117.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,902 on February 18, 2023, 19,903 on February 18, 2024, and 19,903 on February 18, 2025.